Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00800904
First received: December 1, 2008
Last updated: December 2, 2010
Last verified: December 2010

December 1, 2008
December 2, 2010
May 2009
Not Provided
Asthma control test [ Time Frame: On the survey date ] [ Designated as safety issue: No ]
Thai asthma control test [ Time Frame: On the survey date ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00800904 on ClinicalTrials.gov Archive Site
Asthma control in mild, moderate and severe persistent asthma patients [ Time Frame: On the survey date ] [ Designated as safety issue: No ]
Peak expiratory flow rate [ Time Frame: Collect from medical records on the survey date ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand
Asthma Control Among Patients Who Were Receiving Inhaled Corticosteroids in General Practice in Thailand

The purpose of this study is to determine the percentage of patients who has reached the GINA guideline of asthma treatment after receiving any inhaled corticosteroid for 3 months or longer in actual clinical practice. Such percentage for each level of severity - mild, moderate and severe persistent asthma as well as the differences of these rates will also be explored.

Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patient aged 12 years and older who established persistent asthma and currently treated with any inhaled corticosteroid for 3 months or longer.

Asthma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1210
November 2009
Not Provided

Inclusion Criteria:

  • Established persistent asthma
  • Currently treated with any inhaled corticosteroid therapy but not SYMBICORT nor SERETIDE for 3 months or longer

Exclusion Criteria:

  • Currently participating or have participated in a study with an investigational compound within the last 30 days
  • Current diagnosis of chronic obstructive pulmonary disease (COPD)
  • Smoked more than 10 packs a year
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Thailand
 
NCT00800904
NIS-RTH-DUM-2008/1
No
Thanu Komolsai, MD, Medical Advisor, AstraZeneca (Thailand) Ltd.
AstraZeneca
Not Provided
Principal Investigator: Bandit Thinkhamrop, PhD Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University
Principal Investigator: Watchara Boonsawat, MD. PhD Department of Medicine, Faculty of Medicine, Khon Kaen University
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP